A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.
80 moderate cases, HCQ+AZ appears to reduce serious complications and death. Moderate treated cases resulted in hospitalization at the same rate as mild untreated cases suggesting efficacy.
Otea et al., 10 Jun 2020, preprint, 6 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.10.20101105; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
TITLE: A short therapeutic regimen based on hydroxychloroquine plus
azithromycin for the treatment of COVID-19 in patients with moderate disease. A
strategy associated with a reduction in hospital admissions and complications.
AUTHORS: José A. Oteo (1), Pedro Marco (2), Luis Ponce de León (3), Alejandra
Roncero (3), Teófilo Lobera (3), Valentín Lisa (2).
(1) Infectious Disease Department. Hospital Universitario San Pedro and Center of
Biomedical Research of La Rioja (CIBIR). Piqueras 98. 26006 Logroño (Spain)
(2) Emergency Department. Hospital Universitario San Pedro. Piqueras 98. 26006
Logroño (Spain)
(3) Hospital Home-Care Unit. Piqueras 98. 26006 Logroño (Spain)
Conflict of interest disclosure: Nothing to disclose.
Funding: No external funding was received.
Word count: 2,354
Author contributions:
JAO, PM and VL conceived the study; LP, AR and TL supervised the data collection;
JAO and PM drafted the manuscript, and all authors contributed substantially to its
revision. JAO takes responsibility for the paper as a whole.
Corresponding Author:
José A. Oteo, M.D; PhD
Department of Infectious Diseases
Hospital Universitario San Pedro – Centro de Investigación Biomédica de La Rioja
C/Piqueras 98. 26006 Logroño (Spain)
jaoteo@riojasalud.es
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.06.10.20101105; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SUMMARY
The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System.
At the time of writing this paper no medical therapy is officially recommended or has
shown results in improving the outcomes in COVID-19 patients. With the aim of
diminishing the impact in Hospital admissions and reducing the number of medical
complications, we implemented a strategy based on a Hospital Home-Care Unit
(HHCU) using an easy-to-use treatment based on an oral administration regimen outside
the hospital with hydroxychloroquine (HCQ) plus azithromycin (AZM) for a short
period of 5 days.
Patients and methods: Patients ≥ 18 years old visiting the emergency room at the
Hospital Universitario San Pedro de Logroño (La Rioja) between March, 31st and April,
12th diagnosed with COVID-19 with confirmed SARS-CoV-2 infection by a specific
PCR, as follows: Patients with pneumonia (CURB ≤ 1) who did not present severe
comorbidities and had no processes that contraindicated this therapeutic regime.
Olygosimptomatic patients without pneumonia aged ≥ 55 years. Patients ≥ 18 years old
without pneumonia with significant comorbidities. We excluded patients with known
allergies to some of the antimicrobials used and patients treated with other drugs that
increase the QTc or with QTc >450msc. The therapeutic regime was: HCQ 400 mg
every twice in a loading dose followed by 200 mg twice for 5 days, plus AZM 500..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit